Jubilant Pharmova

1,165.40
-34.90
(-2.91%)
Market Cap
18,562.62 Cr
EPS
52.99
PE Ratio
34.25
Dividend Yield
0.41 %
Industry
Healthcare
52 Week High
1,309.90
52 Week Low
701.80
PB Ratio
3.06
Debt to Equity
0.68
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,672.50
#1 4,01,288.77
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,938.00
1,84,182.10
83.40
9,360.00
0.89
2,117
23.05
68.54
1,488.30
1,20,211.16
23.71
28,409.50
7.12
5,291
30.28
54.26
3,322.40
1,12,445.11
59.20
11,539.40
11.59
1,911
10.91
62.08
1,283.80
1,07,142.24
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,431.70
1,00,363.25
50.14
12,207.40
19.57
1,925
-10.91
59.65
983.20
98,932.93
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,922.10
87,781.44
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,160.00
72,587.62
51.77
6,409.15
10.80
1,417
27.83
64.97
1,147.70
66,658.60
19.91
31,378.10
17.55
3,366
-0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
7.15 %
Net Income Growth
-212.02 %
Cash Flow Change
47.01 %
ROE
-211.67 %
ROCE
99.13 %
EBITDA Margin (Avg.)
11.09 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
6,265
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
3,510
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
2,715
Investments
0
85
103
124
115
69
241
239
256
42
1,129
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
68
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
2,165
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
4,353
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
6,255
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
Share Capital
16
16
16
16
16
16
16
16
16
16
16

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
17.22 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
7.05 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
17.75 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
7.31 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 0.00
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Jul 2025 DIVIDEND Dividend
₹ 5.00 /share
25 Jul 2025 945.50 1,199.85
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
16 May 2025 897.95 945.50
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 958.35 973.95
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Oct 2024 1,172.90 1,056.10
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Aug 2024 861.00 919.50
02 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
02 Aug 2024 706.10 850.75
10 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
10 Aug 2023 358.75 450.85
12 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
11 Aug 2022 404.65 350.25
06 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
05 Aug 2021 836.20 667.90
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
01 Feb 2021 926.90 926.90

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20183 days ago
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 16, 2025
Board Meeting Outcome for Outcome Of Board MeetingJun 12, 2025
Announcement under Regulation 30 (LODR)-RestructuringJun 12, 2025
Intimation Under Regulation 30 - Receipt Of Rectification Order From The Income Tax DepartmentJun 11, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 16, 2025
The Company Has Informed The Exchange That Record Date For The Purpose Of Dividend Is July 25 2025.May 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 16, 2025
Corporate Action-Board approves DividendMay 16, 2025
Audited Results For The Quarter And Financial Year Ended March 31 2025May 16, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 16 2025May 16, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 06, 2025
Board Meeting Intimation for 1. The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2025. 2. Recommendation Of Final Dividend If Any For The Financial Year Ended March 31 2025.Apr 30, 2025
Update On Material Development About The Disclosure Made On February 25 2025Apr 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Amended And Restated Deed Of Private Trust Dated March 25 2025Mar 25, 2025
Closure of Trading WindowMar 24, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With PieMar 20, 2025
Announcement Under Regulation 30 - USFDA Report For Jubilant Cadista Pharmaceuticals Inc. USAMar 12, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Audio Recording Of Investors / Analysts MeetingFeb 24, 2025
Presentation For Investor And Analyst MeetFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Integrated Filing (Financial)Jan 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Unaudited Results For The Quarter Ended December 31 2024Jan 31, 2025
Board Meeting Outcome for Outcome Of Board MeetingJan 31, 2025
Announcement Under Regulation 30 - Jubilant Biosys Innovative Research Services Pte Limited Singapore (JBIRSPL) A Subsidiary Of Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has ExeJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
The Company Has Informed The Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 214 Cr.Jan 24, 2025
Board Meeting Intimation for Intimation For Board Meeting Scheduled On January 31 2025 To Consider The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Jan 23, 2025
USFDA Inspection In Companys Subsidiary Jubilant Cadista Pharmaceuticals Inc.Jan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingDec 10, 2024
Deferment Of Investor/ Analysts MeetingNov 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 25, 2024
Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Announcement - Voluntary Prepayment Of USD 25 Million Term Loan, Equivalent To Rs. 210 CrOct 24, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 19, 2024
Board Meeting Intimation for Intimation Of Board MeetingOct 17, 2024

Technical Indicators

RSI(14)
Neutral
66.44
ATR(14)
Volatile
38.58
STOCH(9,6)
Overbought
80.27
STOCH RSI(14)
Neutral
70.83
MACD(12,26)
Bearish
-0.23
ADX(14)
Strong Trend
33.05
UO(9)
Bearish
44.37
ROC(12)
Uptrend And Accelerating
6.53
WillR(14)
Neutral
-25.63

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Quant Small Cap Fund Direct Plan-Growth
0.00%
-2947185
-1.23%
-1.01%
Bandhan Small Cap Fund Direct-Growth
0.00%
-882249
-0.88%
-0.68%
Kotak Contra Fund Direct-Growth
0.00%
-538637
-1.48%
0.00%
Kotak Special Opportunities Fund Direct-Growth
0.00%
-450000
-2.53%
-2.02%
Kotak MNC Fund Direct-Growth
0.00%
-362006
-1.90%
-1.51%
Kotak Consumption Fund Direct - Growth
0.00%
-281413
-2.65%
-2.09%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-258247
-1.78%
-1.29%
Bandhan Innovation Fund Direct-Growth
0.00%
-181004
-1.41%
-1.10%
Kotak Healthcare Fund Direct - Growth
0.00%
-140000
-3.78%
-3.04%
Bandhan Business Cycle Fund Direct-Growth
0.00%
-104445
-0.73%
-0.46%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-90340
-0.47%
-0.39%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-63185
-0.85%
-0.69%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-56669
-0.47%
-0.39%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-47763
-0.85%
-0.69%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-36600
-0.47%
-0.39%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
-34986
-1.28%
-1.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-19846
-0.47%
-0.39%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
-18850
-0.47%
-0.39%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.00%
-9445
-0.05%
-0.04%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.00%
-7921
-0.23%
-0.19%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-5412
-0.47%
-0.39%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
-4892
-0.84%
-0.68%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.00%
-4723
-0.12%
-0.10%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-4437
-0.47%
-0.39%
SBI Nifty 500 Index Fund Direct-Growth
0.00%
-3470
-0.05%
-0.04%

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Chairperson NameShyam S Bhartia